TBC1D3L
gene geneOn this page
Summary
TBC1D3L (TBC1 domain family member 3L, HGNC:51246) is a protein-coding gene on chromosome 17q12, encoding TBC1 domain family member 3L (B9A6J9). Acts as a GTPase activating protein for RAB5.
Predicted to enable GTPase activator activity. Predicted to be located in plasma membrane.
Source: NCBI Gene 101060376 — RefSeq curated summary.
At a glance
- MANE Select transcript:
NM_001369500
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:51246 |
| Approved symbol | TBC1D3L |
| Name | TBC1 domain family member 3L |
| Location | 17q12 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000274512 |
| Ensembl biotype | protein_coding |
| Entrez | 101060376 |
Gene structure
Transcript identifiers
Ensembl transcripts: 5 — 5 protein_coding
ENST00000612727, ENST00000617678, ENST00000851784, ENST00000851785, ENST00000851786
RefSeq mRNA: 4 — MANE Select: NM_001369500
NM_001291459, NM_001369499, NM_001369500, NM_001369501
CCDS: CCDS74043
Canonical transcript exons
ENST00000612727 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003713837 | 37982364 | 37982484 |
| ENSE00003721686 | 37983028 | 37983076 |
| ENSE00003722018 | 37980543 | 37980642 |
| ENSE00003723948 | 37985878 | 37985917 |
| ENSE00003731646 | 37980020 | 37980172 |
| ENSE00003734891 | 37987201 | 37987286 |
| ENSE00003735741 | 37984325 | 37984434 |
| ENSE00003742820 | 37985315 | 37985395 |
| ENSE00003743047 | 37978155 | 37979038 |
| ENSE00003746419 | 37984764 | 37984871 |
| ENSE00003751397 | 37981106 | 37981171 |
| ENSE00003751567 | 37981556 | 37981650 |
| ENSE00003919637 | 37987449 | 37989060 |
Expression profiles
Bgee: expression breadth ubiquitous, 133 present calls, max score 96.63.
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| lower esophagus mucosa | UBERON:0035834 | 96.63 | gold quality |
| right uterine tube | UBERON:0001302 | 94.42 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 90.11 | gold quality |
| metanephros cortex | UBERON:0010533 | 90.10 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 88.99 | gold quality |
| cerebellar cortex | UBERON:0002129 | 88.87 | gold quality |
| cerebellum | UBERON:0002037 | 88.79 | gold quality |
| primary visual cortex | UBERON:0002436 | 88.62 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 87.67 | gold quality |
| right lung | UBERON:0002167 | 87.22 | gold quality |
| pituitary gland | UBERON:0000007 | 86.99 | gold quality |
| granulocyte | CL:0000094 | 86.89 | gold quality |
| right testis | UBERON:0004534 | 86.48 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 86.03 | gold quality |
| endocervix | UBERON:0000458 | 85.97 | gold quality |
| blood | UBERON:0000178 | 85.40 | gold quality |
| esophagus mucosa | UBERON:0002469 | 85.40 | gold quality |
| ectocervix | UBERON:0012249 | 85.33 | gold quality |
| right lobe of liver | UBERON:0001114 | 85.28 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 85.09 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 84.92 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 84.82 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.71 | gold quality |
| vagina | UBERON:0000996 | 84.69 | gold quality |
| skin of leg | UBERON:0001511 | 84.55 | gold quality |
| zone of skin | UBERON:0000014 | 84.04 | gold quality |
| left adrenal gland | UBERON:0001234 | 83.71 | gold quality |
| skin of abdomen | UBERON:0001416 | 83.61 | gold quality |
| right frontal lobe | UBERON:0002810 | 83.61 | gold quality |
| spleen | UBERON:0002106 | 83.53 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.57 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
19 targeting TBC1D3L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-4492 | 99.87 | 68.25 | 3611 |
| HSA-MIR-130B-5P | 99.83 | 68.50 | 1888 |
| HSA-MIR-374C-5P | 99.80 | 72.06 | 2910 |
| HSA-MIR-655-3P | 99.80 | 72.19 | 2909 |
| HSA-MIR-7110-5P | 99.80 | 67.84 | 1712 |
| HSA-MIR-12130 | 99.75 | 65.47 | 452 |
| HSA-MIR-5584-5P | 99.49 | 68.22 | 2814 |
| HSA-MIR-4505 | 99.27 | 67.81 | 2678 |
| HSA-MIR-3940-5P | 99.14 | 65.26 | 493 |
| HSA-MIR-4507 | 99.14 | 65.27 | 515 |
| HSA-MIR-421 | 98.90 | 67.04 | 1883 |
| HSA-MIR-7155-5P | 98.65 | 66.14 | 1290 |
| HSA-MIR-8060 | 98.61 | 66.93 | 1187 |
| HSA-MIR-5585-5P | 97.95 | 68.80 | 1024 |
| HSA-MIR-3135A | 96.41 | 65.30 | 494 |
| HSA-MIR-548AD-3P | 94.39 | 66.04 | 350 |
Cross-species orthologs
0 orthologs
Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3 (ENSG00000274611)
Protein
Protein identifiers
TBC1 domain family member 3L — B9A6J9 (reviewed: B9A6J9)
All UniProt accessions (2): B9A6J9, B3KTC5
UniProt curated annotations — full annotation on UniProt →
Function. Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11.
Subcellular location. Cell membrane.
Post-translational modifications. Ubiquitinated by a CUL7-based E3 ligase, which leads to proteasomal degradation. Palmitoylation is required for membrane localization and protects TBC1D3 from ubiquitination.
Miscellaneous. TBC1D3 is encoded by a collection of very similar paralogs with multiple copies of each paralog, some human genomes encoding well over 50 copies depending on ethnic origin of the donor.
RefSeq proteins (4): NP_001278388, NP_001356428, NP_001356429, NP_001356430 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000195 | Rab-GAP-TBC_dom | Domain |
| IPR035969 | Rab-GAP_TBC_sf | Homologous_superfamily |
| IPR050302 | Rab_GAP_TBC_domain | Family |
Pfam: PF00566
UniProt features (6 total): lipid moiety-binding region 2, chain 1, domain 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-B9A6J9-F1 | 60.31 | 0.25 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 318, 325
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 12 (showing top):
GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, MIR335_3P, MIR5585_5P, chr17q12, MANNE_COVID19_NONICU_VS_HEALTHY_DONOR_PLATELETS_UP, MANNE_COVID19_COMBINED_COHORT_VS_HEALTHY_DONOR_PLATELETS_UP, GOMF_MOLECULAR_FUNCTION_ACTIVATOR_ACTIVITY, WP_17Q12_COPY_NUMBER_VARIATION_SYNDROME, GOCC_ENDOSOME, GOMF_GTPASE_ACTIVATOR_ACTIVITY
GO Biological Process (0):
GO Molecular Function (1): GTPase activator activity (GO:0005096)
GO Cellular Component (3): endosome (GO:0005768), plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| GTPase activity | 1 |
| enzyme activator activity | 1 |
| GTPase regulator activity | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
6 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TBC1D3L | GPR32 | O75388 | 0 |
| TBC1D3L | ERVFRD-1 | P60508 | 0 |
| TBC1D3L | CCDC7 | Q96M83 | 0 |
IntAct
0 interactions, top by confidence:
BioGRID (1): TBC1D3L (Negative Genetic)
ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0
Diamond homologs: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A2AWA9, A6H6A9, A6NDS4, A6NER0, B9A6J9, H2KZZ6, P0C7X1, P35125, Q2M2D7, Q5RAN1, Q5SVR0, Q66K14, Q6DHY5, Q6IPX1, Q80XC3, Q86UD7, Q8IZP1, Q92738, Q9UFV1, Q9Y3P9, A3KGB4, A6QP29, B0R0W9, B7ZAP0, O60343, O60447, O95759, O97790, P58802, P97366, Q0IIM8, Q10496, Q12317, Q12344, Q28CB1, Q3UYK3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
0 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
0 predictions. Top by Δscore:
AlphaMissense
3577 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:37982410:G:C | F207L | 0.974 |
| 17:37982410:G:T | F207L | 0.974 |
| 17:37982412:A:G | F207L | 0.974 |
| 17:37980615:A:G | W286R | 0.917 |
| 17:37980615:A:T | W286R | 0.917 |
| 17:37984820:A:G | W111R | 0.899 |
| 17:37984820:A:T | W111R | 0.899 |
| 17:37984345:G:C | F159L | 0.895 |
| 17:37984345:G:T | F159L | 0.895 |
| 17:37984347:A:G | F159L | 0.895 |
| 17:37985362:A:G | W78R | 0.886 |
| 17:37985362:A:T | W78R | 0.886 |
| 17:37984818:C:A | W111C | 0.862 |
| 17:37984818:C:G | W111C | 0.862 |
| 17:37985360:C:A | W78C | 0.859 |
| 17:37985360:C:G | W78C | 0.859 |
| 17:37982411:A:G | F207S | 0.858 |
| 17:37984426:C:A | K132N | 0.841 |
| 17:37984426:C:G | K132N | 0.841 |
| 17:37982407:C:A | W208C | 0.838 |
| 17:37982407:C:G | W208C | 0.838 |
| 17:37982409:A:G | W208R | 0.836 |
| 17:37982409:A:T | W208R | 0.836 |
| 17:37980613:C:A | W286C | 0.824 |
| 17:37980613:C:G | W286C | 0.824 |
| 17:37981646:A:C | F224L | 0.823 |
| 17:37981646:A:T | F224L | 0.823 |
| 17:37981648:A:G | F224L | 0.823 |
| 17:37983073:C:A | Q167H | 0.822 |
| 17:37983073:C:G | Q167H | 0.822 |
dbSNP variants (sampled 300 via entrez): RS1156546577 (17:37978639 T>C), RS1158490393 (17:37982096 A>G), RS1160230203 (17:37980165 GA>G), RS1160236788 (17:37978557 A>G), RS1162108701 (17:37980387 G>A), RS1164507860 (17:37980211 G>T), RS1165589690 (17:37978651 G>A,T), RS1166725670 (17:37979917 T>G), RS1169708392 (17:37981910 C>T), RS1172051406 (17:37982007 C>A,G,T), RS1172843043 (17:37978999 G>A), RS1173425303 (17:37980038 C>T), RS1176648629 (17:37982008 G>A), RS1176787405 (17:37978433 G>A), RS1177467289 (17:37980052 A>G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
9 total (human), top 9 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aristolochic acid I | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenite | decreases expression, increases abundance | 1 |
| abrine | increases expression | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Vehicle Emissions | increases abundance, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.